Iama therapeutics
WebbDetails: IAMA-6 is a preclinical stage, a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission. Lead Product (s): IAMA-6. Therapeutic Area: Neurology Product Name: IAMA-6. Webb29 juni 2024 · IAMA Therapeutics couples emerging advances in drug discovery and neurobiology to build a leading, next-generation neuroscience pipeline to selectively inhibit the sodium-potassium chloride cotransporter and other therapeutic targets relevant to brain disorders characterized by neuronal imbalance.
Iama therapeutics
Did you know?
Webb31 mars 2024 · IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make Webb29 mars 2024 · IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a …
Webb15 dec. 2024 · IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medici... IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make Webb24 maj 2024 · About IAMA Therapeutics IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of ...
WebbIn 2024, he co-founded Alyra Therapeutics, a start-up currently based in San Diego (USA), whose mission is to treat melanoma and other cancer types with proprietary drugs that target proteins of the ras oncogene … Webb11 apr. 2024 · In March 2024, IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced that preclinical data supporting its IAMA-6 program in focal refractory …
Webb16 okt. 2024 · IAMA Therapeutics, an innovative research line in the field of neurodevelopmental disorders IAMA Therapeutics is a new reality, a pharmaceutical company focused on research and development of innovative drugs that can help and offer different opportunities to children and adolescents with neurodevelopmental disorders. …
Webb12 jan. 2024 · IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make mist-cloaked heraldWebb11 apr. 2024 · In March 2024, IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of ... mist-cloakedWebbAt IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children … mist cloaked heraldWebb25 juli 2024 · IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children and adults... mist cloak mistbornWebb13 mars 2024 · IAMA Therapeutics pushes the boundaries of neuroscience drug discovery to develop new therapeutic opportunities and make a difference in the lives of … mist clock radio with weather forecastWebbLet us know. Offices: Genoa. Industry: Health services Manufacturing Pharma. Business model: B2B. IAMA Therapeutics is a pharma startup from Italy working on neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Investors: we tracked 2 investors. mist clockWebbIAMA Therapeutics. PhD. Contact. Connect with experts in your field. Join ResearchGate to contact this researcher and connect with your scientific community. Join for free. Log in. Contact. mistcloud.efleetsystems.com login